ID   NOY1
AC   CVCL_0P30
SY   NOY-1; Nagoya Ovarian Yolk sac tumor cell line clone 1
DR   BTO; BTO_0005874
DR   Kerafast; ENG101
DR   Wikidata; Q54930934
RX   PubMed=18547965;
RX   PubMed=21150160;
CC   Population: Japanese.
CC   Doubling time: 28 hours (PubMed=18547965).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C8107; Ovarian yolk sac tumor
DI   ORDO; Orphanet_876; Yolk sac tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0P31 ! NOY2
SX   Female
AG   28Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 9
CH   CVCL_0P32 ! NOY1-CR
//
RX   PubMed=18547965; DOI=10.1159/000139138;
RA   Shibata, Kiyosumi
RA   Kajiyama, Hiroaki
RA   Yamamoto, Eiko
RA   Terauchi, Mikio
RA   Ino, Kazuhiko
RA   Nawa, Akihiro
RA   Kikkawa, Fumitaka
RT   "Establishment and characterization of an ovarian yolk sac tumor cell
RT   line reveals possible involvement of Nkx2.5 in tumor development.";
RL   Oncology 74:104-111(2008).
//
RX   PubMed=21150160; DOI=10.1159/000320744;
RA   Shibata, Kiyosumi
RA   Umezu, Tomokazu
RA   Sakurai, Maiko
RA   Kajiyama, Hiroaki
RA   Yamamoto, Eiko
RA   Ino, Kazuhiko
RA   Nawa, Akihiro
RA   Kikkawa, Fumitaka
RT   "Establishment of cisplatin-resistant ovarian yolk sac tumor cells and
RT   investigation of the mechanism of cisplatin resistance using this cell
RT   line.";
RL   Gynecol. Obstet. Invest. 71:104-111(2011).
//